{
    "2021-09-05": [
        [
            {
                "time": "2021-09-05",
                "original_text": "恒瑞医药向天广实投资3000万美元 双方合作推进MIL62商业化及研发",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "天广实",
                        "MIL62",
                        "商业化",
                        "研发"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-09-05",
                "original_text": "恒瑞医药与天广实生物就第三代抗CD20抗体商业化及联合开发达成合作",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "天广实生物",
                        "抗CD20抗体",
                        "商业化",
                        "联合开发"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-09-05",
                "original_text": "恒瑞医药(600276.SH)与天广实生物达成MIL62商业化及联合用药临床开发合作",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "天广实生物",
                        "MIL62",
                        "商业化",
                        "联合用药",
                        "临床开发"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-09-05",
                "original_text": "恒瑞医药：与天广实生物达成MIL62商业化及联合用药临床开发合作",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "天广实生物",
                        "MIL62",
                        "商业化",
                        "联合用药",
                        "临床开发"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-09-05",
                "original_text": "惨烈爆仓！21股腰斩，最牛赛道怎么突然崩了？",
                "features": {
                    "keywords": [
                        "爆仓",
                        "腰斩",
                        "赛道",
                        "崩盘"
                    ],
                    "sentiment_score": -0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}